Instead of the EGFR T790M mutation, which is the well-known resistance mechanism after the use of first- or second-generation EGFR-TKI42,43, other co-existing genomic alterations have also been widely studied in patients with EGFR-mutant NSCLC received EGFR-TKI. Here, EGFR is linked to non-small cell lung carcinoma.